Abstract:e20036 Background: Mucosal melanoma (MM) is the second common subtype in Asians with a percentage of 22-25%; but there have been few epidemiologic studies. So we performed a retrospective analysis of MM about its clinical presentation, gene mutation, systemic therapy (tx) and prognosis. Methods: Using institutional databases, we identified patients (pts) with MM who were treated in Chinese melanoma centers between 2006-2014 with basic demographics and clinical outcomes. Results: 463 MM pts were included. Median age at diagnosis 56 years (range, 17-86); 61% female; primary site: 149 anal-rectal, 125 genitourinary, 174 head/neck, 15 others. Mutation (mut) status: 14.1% (45/319) KIT mut; 9.7% (31/319) BRAF mut; 10.3% (33/319) NRAS mut. Stage I-II/ III/IV at referring – 36%/17%/47%, M1a/b/c – 17%/18%/65%. The median overall survival (mOS) was 28.0 mo (95% CI 25.1-30.9 mo). Multivariate analysis showed that clinical stage and LDH level were significant prognostic factors for OS. The application of adjuvant therapy and LDH level were significant prognostic factors for disease free survival. For 293 pts who developed stage IV, mOS was 14.0 mo, for M1a, M1b, M1c, 20.2, 16.0, 11.1 mo respectively (p = .004). In 1st-line setting, the objective response rate (RR), disease control rate (DCR) and median progress free time (PFS) was 11.8%, 54.8%, and 3.1 mo (95% CI 2.6-3.8 mo), most of the pts using dacarbazine/temozolomide, cisplatin plus rhEndostatin had RR, DCR and PFS, 12.3%, 64.6%, and 4.5 mo respectively. In 2nd-line setting, paclitaxel plus carboplatin was common regimen, RR, DCR and PFS was 8.3% 61.1% and 3.3 mo (95% CI 2.0-4.4 mo). The mPFS of 3rd-line tx (including Abraxane, investigational targeted drugs, etc) was 1.3 mo without complete regression and partial regression. 8/20 pts harboring c-kit mutation used imatinib, 3/8 pts had SD for a median PFS of 6.7 mo. 5/15 pts harboring BRAF mutation used vemurafenib, 3/5 pts got response, mPFS cannot be evaluated. Conclusions: The prognosis for MM is still poor, clinical stage has its significance for OS. For pts with stage IV, the efficacy of systemic tx includes chemotherapy and targeted therapy is modest. Further investigation into the biology and treatment of MM is needed.

Gene Mutation Characteristics and Clinical Prognosis of Head and Neck Mucosal Melanoma

Gene mutations and clinical prognosis of mucosal melanoma in different locations of head and neck

Clinical Presentation, Systemic Therapy and Prognosis of Mucosal Melanoma, A Study of 463 Consecutive Cases

Comprehensive Genomic Profiling Reveals Distinct Patterns of Driver Mutations and Chromosomal Alterations in Acral and Mucosal Melanomas.

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature.

Analysis of gene mutations and clinical features in elderly patients with melanoma

Characteristics and prognosis of primary mucosal melanoma of nasal cavity and paranasal sinuses: a clinical analysis of 94 patients

Mutational Profiling of Melanomas in Patients from the Southeast Coast of China.

Whole-exome Sequencing Reveals Mutational Profiles of Anorectal and Gynecological Melanoma

Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis

Genetic Analysis of Melanoma Types Using Japanese Genomic Database

Genotyping of Mucosal Melanoma.

Distinct Genomic Traits Of Acral And Mucosal Melanomas Revealed By Targeted Mutational Profiling

Genetic Alteration of Chinese Patients with Rectal Mucosal Melanoma.

Multivariate Analysis of Prognostic Factors among 706 Mucosal Melanoma Patients.

879P Whole-genome Landscape of Head and Neck Melanomas in East Asia (China)

Prevalence of BRAF V600E Mutation in Chinese Melanoma Patients: Large Scale Analysis of BRAF and NRAS Mutations in a 432-Case Cohort.

Clinicopathologic Features and Prognostic Value of KRAS, NRAS and BRAF Mutations and DNA Mismatch Repair Status: A Single‐center Retrospective Study of 1,834 Chinese Patients with Stage I–IV Colorectal Cancer